Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research in Liver Diseases
April 09 2019 - 12:00PM
Business Wire
– Funding will Support Research to Advance
Scientific Understanding and Improve Patient Care in Viral
Hepatitis, Co-Infection, Nonalcoholic Steatohepatitis and Primary
Sclerosing Cholangitis –
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch
of five new global grants programs to continue to support
investigator-sponsored research in chronic hepatitis C virus (HCV)
and hepatitis B virus (HBV), HCV and HIV co-infection, nonalcoholic
steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
The programs will accept applications from around the world for
projects that seek to address pressing unmet patient needs in liver
disease, including improving screening and linkage to care,
simplifying HCV testing and treatment, developing innovative
referral pathways to help patients with NASH access care,
addressing gaps in HBV care for special populations and
understanding PSC epidemiology.
“It takes more than medicine alone to improve the lives of
people living with liver diseases. In HCV, understanding optimal
ways to simplify testing and treatment is critical to reaching
diverse populations living with the disease. People living with
NASH need to access earlier diagnoses and clearer referral pathways
to help them access care,” said Bill Guyer, Senior Vice President,
Head of Medical Affairs, Gilead Sciences. “Gilead is proud to
support investigator-sponsored research areas across liver
diseases, which we believe can help broaden understanding of how to
manage these diseases and help patients be appropriately linked to
care.”
The new grant programs are:
- HCV STAT (Simplification and Test and Treat Strategies toward HCV Elimination)This
program will fund approximately fifteen projects with a total
commitment of US $10M focused on simplifying HCV care delivery and
implementing test and treat strategies to overcome barriers to
patient care. Applications will be accepted from April 11 to June
30, 2019.STAT is the latest addition to the LEGA-C platform,
“Local Elimination Programs Leading to Global Action in
HCV” and includes the ongoing programs
CITE, SCALE, CHIME, and NoCo. To date, Gilead has committed $50M to
support 79 elimination projects around the world through
LEGA-C.
- HIV/HCV NoCo (No Co-Infection)In the third installment of NoCo,
this program will fund approximately six to eight projects with a
total commitment of US $3M focused on investigating strategies to
link patients living with HCV and HIV co-infection to HCV
treatment. Applications will be accepted from May 1 to June 14,
2019.
- NASH Models of CareThis program
will fund approximately eight to ten projects with a total
commitment of US $4M focused on investigating care pathways between
multidisciplinary providers for screening, identifying, and helping
to refer high-risk patients living with NASH to appropriate medical
care. Applications will be accepted from June 3 to July 15,
2019.
- HBV CARE (Linkage to CARe & Epidemiology in Special Populations)This
program will fund approximately six projects with a total
commitment of US $1M focused on improving linkage to care among
underserved population and analyzing or identifying data gaps in
HBV epidemiology in specific demographics or geographies.
Applications will be accepted from August 1 to September 15,
2019.
- PSC PACE (PrimAry Sclerosing
Cholangitis Epidemiology)This program will fund up to five
projects with a total commitment of US $1M focused on identifying
gaps in PSC epidemiology data and improving understanding of the
cascade of care. Applications will be accepted from September 16 to
October 11, 2019.
For more information on Gilead’s new liver disease grants
programs, please visit
https://www.gilead.com/science-and-medicine/research/investigator-sponsored-research.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
California.
For more information on Gilead Sciences, please
visit the company’s website at www.gilead.com, follow Gilead on
Twitter (@GileadSciences) or call Gilead Public Affairs at
1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190409005654/en/
Sung Lee, Investors(650) 524-7792
Arran Attridge, Media(650) 425-8975
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024